Article Figures & Data
Figures
- Figure 1.
Pathologic Complete Response by HR Status in NeoALTTO
HR, hormone receptor.
Reprinted from The Lancet, Copyright 2012;379:633-640, Baselga J et al, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. With permission from Elsevier.
Tools
Table of contents
Cited By...
- No citing articles found.